Comparative Pharmacology
Head-to-head clinical analysis: SUPPRELIN LA versus VANTAS.
Peer-Reviewed Evidence
Head-to-head clinical analysis: SUPPRELIN LA versus VANTAS.
SUPPRELIN LA vs VANTAS
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
SUPPRELIN LA is a sterile, biodegradable, subcutaneous implant containing histrelin acetate, a synthetic nonapeptide agonist of gonadotropin-releasing hormone (GnRH). After an initial transient increase, continuous administration results in downregulation of pituitary GnRH receptors, leading to suppressed luteinizing hormone (LH) and follicle-stimulating hormone (FSH) secretion, thereby reducing gonadal sex steroid production (testosterone in males, estradiol in females) to castrate levels.
Gonadotropin-releasing hormone (GnRH) agonist; continuous stimulation suppresses pituitary gonadotropin secretion, resulting in decreased testosterone production.
50 mg subcutaneously once every 12 months (implant placed in inner upper arm).
10 mg subcutaneously every 24 weeks.
None Documented
None Documented
Terminal half-life approximately 3-4 hours; clinical suppression of luteinizing hormone and testosterone sustained for 4 weeks due to depot formulation.
Terminal elimination half-life approximately 4 weeks (28 days) due to continuous release from the implant; after implant removal, plasma concentrations decline with a half-life of about 3-4 days.
Renal: <5% unchanged; hepatic metabolism; fecal elimination of metabolites.
Renal: negligible. Fecal: ~100% (unchanged drug). Histrelin is not metabolized and is excreted unchanged in feces via biliary elimination.
Category C
Category C
GnRH Agonist
GnRH Agonist